Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?

Texto completo
Autor(es):
Mostrar menos -
Nani, V, Joao ; Dal Mas, Caroline [1] ; Yonamine, Camila M. [1] ; Ota, Vanessa K. [2] ; Noto, Cristiano [3, 4] ; Belangero, I, Sintia ; Mari, Jair J. [3] ; Bressan, Rodrigo [3] ; Cordeiro, Quirino [4] ; Gadelha, Ary [3] ; Hayashi, Mirian A. F. [1, 5]
Número total de Autores: 11
Afiliação do(s) autor(es):
[1] Nani, Joao, V, Univ Fed Sao Paulo UNIFESP, Dept Pharmacol, Sao Paulo - Brazil
[2] I, Univ Fed Sao Paulo UNIFESP, Dept Genet, Sao Paulo - Brazil
[3] Nani, Joao, V, Univ Fed Sao Paulo UNIFESP, Dept Psychiat, Sao Paulo - Brazil
[4] Univ Fed Sao Paulo UNIFESP, First Episode Psychosis Program, Sao Paulo - Brazil
[5] Nani, Joao, V, CNPq, Natl Inst Translat Med INCT TM, Ribeirao Preto - Brazil
Número total de Afiliações: 5
Tipo de documento: Artigo Científico
Fonte: INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY; v. 23, n. 11, p. 721-730, NOV 2020.
Citações Web of Science: 0
Resumo

Background: Our previous studies showed increased angiotensin I-converting enzyme (ACE) activity in chronic schizophrenia patients compared with healthy control (HC) volunteers, and the relevance of combining ACE genotype and activity for predicting schizophrenia was suggested. Methods: ACE activity was measured in plasma of ACE insertion/deletion (I/D) genotyped HC volunteers (n = 53) and antipsychotic-naive first-episode psychosis (FEP) patients (n = 45) assessed at baseline (FEB-B) and also after 2 months (FEP2M) of treatment with the atypical antipsychotic risperidone. Results: ACE activity measurements showed significant differences among HC, FEP-B, and FEP-2M groups (F = 5.356, df = 2, P =.005) as well as between HC and FEP-2M (post-hoc Tukey's multiple comparisons test, P =.004). No correlation was observed for ACE activity increases and symptom severity reductions in FEP as assessed by total Positive and Negative Syndrome Scale (r = -0.131, P =.434). FEP subgrouped by ACE I/D genotype showed significant ACE activity increases, mainly in the DD genotype subgroup. No correlation between ACE activity and age was observed in FEP or HC groups separately (r = 0.210, P =.392), but ACE activity level differences observed between these groups were influenced by age. Conclusions: The importance of measuring the ACE activity in blood plasma, associated with ACE I/D genotyping to support the follow-up of FEP patients, did not show correlation with general symptom amelioration in the present study. However, new insights into the influence of age and I/D genotype for ACE activity changes in FEP individuals upon treatment was demonstrated. (AU)

Processo FAPESP: 17/25016-8 - Investigação da resposta ao tratamento da esquizofrenia com risperidona: estudo farmacogenético em uma coorte de pacientes em primeiro episódio psicótico
Beneficiário:Síntia Iole Nogueira Belangero
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 17/02413-1 - Validação da crotamina como biomarcador e avaliação do seu potencial uso na terapia de doenças humanas
Beneficiário:Mirian Akemi Furuie Hayashi
Linha de fomento: Auxílio à Pesquisa - Regular
Processo FAPESP: 12/08941-6 - Estudo das oligopeptidases na esquizofrenia
Beneficiário:Camila Miyagui Yonamine Asanuma
Linha de fomento: Bolsas no Brasil - Pós-Doutorado
Processo FAPESP: 19/09207-3 - Estudo do(s) mecanismo(s) molecular(es) e celular(es) em transtornos mentais
Beneficiário:João Victor Silva Nani
Linha de fomento: Bolsas no Brasil - Doutorado